Cytokinetics, Incorporated (CYTK) Shares Down 5.9%
Cytokinetics, Incorporated (NASDAQ:CYTK) fell 5.9% during trading on Monday . The company traded as low as $11.15 and last traded at $11.10. 847,354 shares traded hands during trading, an increase of 61% from the average session volume of 525,705 shares. The stock had previously closed at $11.80.
A number of equities research analysts recently issued reports on the stock. Cantor Fitzgerald cut shares of Cytokinetics, from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $21.00 to $10.00 in a research note on Wednesday. ValuEngine cut shares of Cytokinetics, from a “hold” rating to a “sell” rating in a research note on Tuesday. Cowen and Company reissued a “buy” rating and issued a $19.00 price target on shares of Cytokinetics, in a research note on Friday, August 4th. Morgan Stanley reissued an “overweight” rating and issued a $17.00 price target (down previously from $25.00) on shares of Cytokinetics, in a research note on Wednesday. Finally, HC Wainwright set a $26.00 price target on shares of Cytokinetics, and gave the company a “buy” rating in a research note on Thursday, August 3rd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $17.64.
The company has a quick ratio of 7.60, a current ratio of 7.60 and a debt-to-equity ratio of 0.14.
Cytokinetics, (NASDAQ:CYTK) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.64) by $0.04. The company had revenue of $6.18 million during the quarter, compared to the consensus estimate of $5.35 million. Cytokinetics, had a negative return on equity of 62.64% and a negative net margin of 172.27%. research analysts forecast that Cytokinetics, Incorporated will post -2.4 earnings per share for the current fiscal year.
In related news, insider Caryn Gordon Mcdowell sold 4,260 shares of the company’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $12.94, for a total value of $55,124.40. Following the completion of the transaction, the insider now directly owns 17,982 shares of the company’s stock, valued at $232,687.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Robert I. Blum sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $14.71, for a total value of $73,550.00. Following the completion of the transaction, the chief executive officer now directly owns 79,785 shares of the company’s stock, valued at $1,173,637.35. The disclosure for this sale can be found here. Over the last three months, insiders have sold 178,223 shares of company stock valued at $2,639,239. Corporate insiders own 7.20% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in CYTK. State of Alaska Department of Revenue purchased a new stake in Cytokinetics, in the second quarter valued at approximately $109,000. Municipal Employees Retirement System of Michigan purchased a new stake in Cytokinetics, in the second quarter valued at approximately $132,000. Birchview Capital LP purchased a new stake in Cytokinetics, in the third quarter valued at approximately $145,000. Piedmont Investment Advisors LLC purchased a new stake in Cytokinetics, in the third quarter valued at approximately $159,000. Finally, BNP Paribas Arbitrage SA lifted its stake in Cytokinetics, by 4,464.4% in the second quarter. BNP Paribas Arbitrage SA now owns 13,328 shares of the biopharmaceutical company’s stock valued at $161,000 after buying an additional 13,036 shares during the last quarter. 71.92% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/cytokinetics-incorporated-cytk-shares-down-5-9/1719996.html.
Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.
Receive News & Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.